Johnson & Johnson
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 9, 2024), Johnson & Johnson reported 20 stock positions worth $400.7 million. Its top holding was Protagonist Therapeutics (PTGX) at 21.2% of the portfolio, followed by Rapport Therapeutics (RAPP, 14.5%) and CVRX (CVRX, 12.3%). Compared with Q1 2024, it opened 3 new positions and sold out of 5. The biggest buy was a new position in Rapport Therapeutics (RAPP) and the biggest sale an exit from Kenvue (KVUE).
- Most Recent 13F
- Q2 2026
- Location
- NEW BRUNSWICK, NJ
- CIK
- 0000200406
- Portfolio Value
- $400.7M (Q2 2024)
- SEC Filing
- 0000904454-24-000451 ↗ filed Aug 9, 2024
Holdings Value
Holdings 20 stocks · $400.7M
| PTGX Protagonist Therapeutics Inc. | 21.18% | 2,449,183 | $84.9M | No change |
| RAPP Rapport Therapeutics Inc. | 14.50% | 2,498,051 | $58.1M | New |
| CVRX CVRX Inc. | 12.28% | 4,103,430 | $49.2M | No change |
| LEGN Legend Biotech Corp.-ADR | 9.00% | 814,586 | $36.1M | No change |
| CTNM Contineum Therapeutics Inc. Class A | 8.70% | 1,979,173 | $34.9M | New |
| NBTX Nanobiotix SA - ADR | 7.02% | 5,623,816 | $28.1M | No change |
| MGTX Meiragtx Holdings PLC | 6.98% | 6,641,064 | $28.0M | No change |
| PRCT Procept Biorobotics Corp. | 5.46% | 357,939 | $21.9M | No change |
| NMRA Neumora Therapeutics Inc. | 4.54% | 1,849,445 | $18.2M | No change |
| XNCR Xencor Inc. | 3.53% | 748,062 | $14.2M | No change |
| FATE Fate Therapeutics Inc. | 2.77% | 3,379,064 | $11.1M | No change |
| ARWR Arrowhead Pharmaceuticals Inc. | 1.61% | 247,598 | $6.4M | No change |
| RLYB Rallybio Corp. | 1.22% | 3,636,363 | $4.9M | New |
| NNOX Nano-X Imaging Ltd. | 0.29% | 158,852 | $1.2M | No change |
| VOR Vor Biopharma Inc. | 0.27% | 1,074,658 | $1.1M | No change |
| ALDX Aldeyra Therapeutics Inc. | 0.25% | 299,669 | $992K | No change |
| BIOMX INC | 0.16% | 1,923,201 | $646K | No change |
| LAB Standard Biotools Inc. | 0.14% | 311,967 | $552K | No change |
| ACET Adicet Bio Inc. | 0.11% | 364,472 | $441K | No change |
| SENS Senseonics Holdings Inc. | 0.01% | 54,621 | $22K | No change |
Portfolio Sells Q1 2024 → Q2 2024
| KVUE Kenvue Inc. | Sold out | 0.00% | −88.66 |
| FUSN Fusion Pharmaceuticals Inc. | Sold out | 0.00% | −1.77 |
| SWAV Shockwave Medical Inc. | Sold out | 0.00% | −1.23 |
| CLEARSIDE BIOMEDICAL INC | Sold out | 0.00% | −0.01 |
| TRACON PHARMACEUTICALS INC | Sold out | 0.00% | −0.00 |
Portfolio Buys Q1 2024 → Q2 2024
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 15 | $798.7M | PTGX, NBTX, MGTX, RAPP, CTNM |
| Q1 2026 | 16 | $652.4M | PTGX, NBTX, MGTX, RAPP, CVRX |
| Q4 2025Amended | 17 | $555.0M | PTGX, NBTX, RAPP, MGTX, CVRX |
| Q3 2025Amended | 20 | $503.9M | PTGX, NBTX, MGTX, RAPP, CVRX |
| Q2 2025 | 20 | $334.1M | PTGX, MGTX, RAPP, LEGN, NBTX |
| Q1 2025 | 20 | $341.9M | PTGX, CVRX, MGTX, LEGN, RAPP |
| Q4 2024 | 20 | $386.1M | PTGX, CVRX, RAPP, MGTX, CTNM |
| Q3 2024 | 20 | $427.3M | PTGX, RAPP, LEGN, CTNM, CVRX |
| Q2 2024 | 20 | $400.7M | PTGX, RAPP, CVRX, LEGN, CTNM |
| Q1 2024 | 22 | $4.4B | KVUE, FUSN, CVRX, PTGX, SWAV |